Ionis Pharmaceuticals Inc (IONS) — Titan Protect Analysis

IONS

Ionis Pharmaceuticals Inc

Healthcare · ·

$74.48

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$12.0B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-116.66

Based on estimated future earnings — lower means cheaper

Rev Growth

+87.0%

Year-over-year revenue change

Profit Margin

-30.9%

How much profit the company keeps from each dollar of revenue

ROE

-67.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$105.00

+41% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 25 analysts covering this stock

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat

https://www.ionis.com

Country: United States Employees: 1,402 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.925

Good returns relative to risk taken

Kelly Fraction

0.0803

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.739

Acceptable balance between returns and drawdown risk

Annual Return

37.5%

Historical annualised return based on price data

Max Drawdown

-50.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

170

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.38

Very low correlation to market moves

52W High

$86.74

14% below the year high

52W Low

$34.72

115% above the year low

Avg Volume

1,955,193

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.01

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

531.05

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

10.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-47.7%

Profit from core operations before interest and tax

Free Cash Flow

$-807,796,352

Negative — the business is spending more than it generates

Revenue (TTM)

$1.1B

Total revenue over the last 12 months

Net Income

$-326,976,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$130.00

Target Median

$105.00

Target Low

$47.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-21	Ro Khanna	Democrat	Sale	1K–15K
2026-04-20	Ro Khanna	Democrat	Sale	15K–50K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Sale	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go